Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction
- 22 October 2022
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 186, 150-155
- https://doi.org/10.1016/j.amjcard.2022.09.019
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureThe New England Journal of Medicine, 2021
- 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection FractionJournal of Invasive Cardiology, 2021
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureThe New England Journal of Medicine, 2020
- Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEFJACC: Heart Failure, 2020
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to AgeJournal of the American College of Cardiology, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionThe New England Journal of Medicine, 2019
- Canagliflozin and Heart Failure in Type 2 Diabetes MellitusJournal of the American College of Cardiology, 2018
- Improving Medication Adherence in Cardiometabolic DiseaseJournal of Invasive Cardiology, 2017
- Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta‐Analysis of Controlled TrialsJournal of the American Heart Association, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016